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depletion, and the prevention of progression of glomerularPodocyte depletion and glomerulosclerosis have a direct rela-
diseases.tionship in the PAN-treated rat.
Background. Podocytes are highly differentiated glomerular
epithelial cells with limited potential to divide. They are respon-
sible for maintaining and supporting the glomerular basement The podocyte is a highly differentiated epithelial cell
membrane so as to facilitate efficient filtration. The hypothesis
with limited capacity to divide and therefore to be replacedtested was whether the development of glomerulosclerosis in
if lost [1–4]. The octopus-shaped podocyte functions tothe puromycin aminonucleoside (PAN)-treated rat could be
attributed to podocyte depletion. support and maintain the filtration surface (glomerular
Methods. PAN was injected in Sprague-Dawley rats once, basement membrane) via major, intermediate, and mi-
twice, or three times at 30-day intervals. Podocytes were counted nor (“foot”) processes that interdigitate between neigh-in glomeruli using immunoperoxidase histochemistry and anti-
boring cells [5]. This support structure serves to counter-bodies to both GLEPP1 (PTPRO) and WT-1. Podocytes were
balance the hydrostatic filtration force of blood pressureassayed in urine using reverse transcription-quantitative poly-
merase chain reaction (RT-QPCR). Glomerular areas were driving the filtration process and at the same time tending
measured by computerized morphometry. to expand glomerular capillaries [6]. The destiny of a
Results. In a preliminary experiment, a single injection of
podocyte is therefore to cling by its foot processes to thePAN caused a reduction in the glomerular podocyte count
outer surface of the filter, while the thrust of the forcesby 25%. Additional independent confirmation that podocytes
were lost from glomeruli after PAN injection was obtained of filtration tends to blow it off its perch. Any factor
identifying detached podocytes in Bowman’s space, measure- tending to reduce the ability of a podocyte to remain
ment of nephrin and GLEPP1 mRNAs in urine, ultrastructural attached to the glomerular basement membrane (GBM)analysis of glomeruli, and identification of TUNEL-positive
or to increase filtration forces will therefore tend to pro-apoptotic podocytes in glomeruli. In a second experiment, se-
mote detachment of podocytes from the glomerulus. Cho,quential podocyte depletion by 15, 31, and 53% was achieved
by the administration of one, two, or three injections of PAN Lumsden, and Whiteside have emphasized via mathe-
at 30-day intervals. The region of the glomerulus devoid of matical modeling how partial detachment may tend to
podocytes developed glomerulosclerosis, and this area progres-
lead to further podocyte detachment [7].sively increased as podocytes were progressively depleted. The
Podocytes are particularly susceptible to toxic injurycorrelation coefficient (r2) value for the relationship between
percent podocyte depletion and glomerulosclerotic area was from oxidants. This is demonstrated by the finding that
0.99. The Y intercept of this plot showed that glomerulosclero- podocyte injury and glomerulosclerosis are the major phe-
sis was initiated when only 10 to 20% of podocytes were lost. notypes of an antioxidant-defective mouse [8]. Similarly,Conclusion. This report supports the growing body of data
puromycin aminonucleoside (PAN), which induces oxi-linking glomerulosclerosis directly to a reduction in relative
dant injury in cells via the xanthine oxidase pathway, haspodocyte number [increased glomerular area per podocyte
(GAPP)]. It raises important questions related to the mecha- been used extensively as a model of podocyte injury [9].
nisms of podocyte loss, strategies for prevention of podocyte Podocyte injury in this model can be ameliorated by inhib-
itors of oxidants [10, 11]. Following PAN injection, injury
in the rat podocytes is manifest by loss of interdigitatingKey words: progressive renal disease, epithelial cells, foot processes,
glomerular basement membrane, oxidant injury. foot processes, detachment from the GBM, pseudocyst
formation, reduction in anionic charge, attenuation of the
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process [focal glomerulosclerosis (FGS)] [17]. FGS in METHODS
humans is commonly associated with progression to end- Animal model of PAN nephrosis
stage renal disease (ESRD) requiring renal replacement In an initial experiment, male Sprague-Dawley rats
therapy [18]. weighing approximately 100 g were administered intra-
The maintenance of normal glomerular structure and peritoneal PAN (Sigma Company, St. Louis, MO, USA)
function requires the interaction between all three glo- at a dose of 20 mg/100 g body weight or an equivalent
merular cell types, including podocytes, mesangial, and volume of 0.9% saline. Urine was collected over a 24-
endothelial cells. As emphasized by Kriz, Gretz, and Lem- hour period at day 2 through day 11 and at days 21,
ley, failure of any one of these systems may lead to the 45, 80, and 126. Groups of rats (N  4 to 5 per group)
same result, namely glomerulosclerosis [3]. Elegant stud- were sacrificed at day 1 (control) and at days 5, 7,
ies in a wide range of experimental models and in humans 11, 21, 45, 80, and 126. A second control group was
have suggested that podocyte injury and loss might be maintained with the experimental group until day 126
a central factor leading to glomerulosclerosis [1–4, 6, 12, for comparison with the experimental day 126 group. In
17, 19–30]. a second experiment, groups of 100 g Sprague-Dawley
Recent information supports the concept that podo- rats were kept for 90 days before sacrifice. They received
cyte number may be a key factor dictating the progression either no PAN or PAN once, twice, or three times at
of glomerular sclerosis in the type II diabetic Pima Indian 30-day intervals. Thus, the three-injection group received
population. In these studies, Pagtalunan et al showed that PAN at day 0, day 30, and day 60 and were sacrificed
individuals who had more advanced proteinuria (macro- at day 90, which was 30 days after the last injection. For
albuminuria) and glomerular matrix accumulation (dia- each rat, 24-hour urine collections were performed to
measure the 24-hour urine protein excretion and an ali-betic glomerulosclerosis) had fewer glomerular podo-
quot of urine was processed for reverse transcription-cytes than did individuals who had experienced diabetes
polymerase chain reaction (RT-PCR) analysis for GLEPP1for the same length of time but who were not proteinuric
and nephrin mRNA measurements (discussed later inand glomerulosclerotic [31]. In contrast, other glomerular
this article). At day 90, the rats were killed, and kidneyscells did not decrease in number in the same glomeruli. In
were perfused with phosphate-buffered saline for twoa follow-up report, diabetic Pima Indians with a depleted
minutes, followed by paraformaldehyde in phosphatepodocyte population tended to progress toward macro-
buffer for eight minutes at a pressure of 120 mm Hg.albuminuria faster than did those who had a greater
After perfusion, kidneys were quickly removed, and 3 tocomplement of podocytes four years earlier [32]. Hara et
4 mm sections of kidney were cut for fixation in formalin.al have shown that in human glomerular diseases podo-
cytes are lost into the urine, where they can be detected Immunoperoxidase histochemistry
by immunofluorescent approaches [33]. This latter report
Three micrometer-thick formalin-fixed, paraffin-embed-therefore provides direct confirmation that podocytes
ded sections were deparaffinized, hydrated, and treatedmay be lost from glomeruli into urine in humans.
with target unmasking fluid (Signet Labs, Dedham, MA,To understand this process better, we therefore at-
USA) for two hours at 90C. Immunoperoxidase stainingtempted to develop a model in which could sequentially
was performed according to the Vectastatin ABC kit
deplete podocytes. We observed that a single dose of PAN
(Vector Laboratories, Burlingame, CA, USA). The pri-
caused a limited reduction in podocyte number associ- mary antibodies used were a monoclonal antibody raised
ated with minor glomerulosclerosis. Therefore, one, two, against the rat GLEPP1 extracellular domain (1B4) and
or three doses of PAN were used in rats administered at a commercially available rabbit polyclonal antibody to
30-day intervals to induce progressive podocyte depletion. Wilms’ tumor-1 protein (WT-1; Santa Cruz Biotechnol-
A very close relationship between the number of podocytes ogy, Santa Cruz, CA, USA). These markers are podocyte
lost and the degree of glomerulosclerosis was found. The specific in the mature kidney [34, 35]. The Thy-1 antibody
capacity of a podocyte to cover additional territory was (PharMingen, San Diego, CA, USA) was used as a marker
limited so that a reduction in podocyte number per unit for mesangial and other cells [36]. The detection system
area [designated as glomerular area per podocyte (GAPP)] used diaminobenzidine (DAB). Periodic acid-Schiff (PAS)
above a threshold level was associated with development and hematoxylin were used as a counterstain.
of glomerulosclerosis. Furthermore, glomerulosclerosis
TUNEL assayoccurred in those areas of the glomerulus in which podo-
cytes, as defined by the specific markers GLEPP1 or To detect apoptotic cells, the TUNEL assay was per-
WT1, were absent. These data provide support for the formed using the In Situ Cell Death Detection Kit (Boeh-
concept that podocyte depletion beyond a certain thresh- ringer Manheim, Indianapolis, IN, USA). Formalin-fixed,
paraffin-embedded sections were stripped of proteinsold level leads directly to glomerulosclerosis.
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by incubation with proteinase K (20 g/mL; GIBCO, This number, the CT value, varies directly with the abun-
dance. To derive the relative abundance measures ofGaithersburg, MD, USA) and stained according to man-
ufacturer’s instructions. Terminal deoxynucleotidyl trans- two sequences in a given DNA sample, the CT value
derived using the first sequence with the given RNAferase (TdT) was omitted from the nucleotide mixture
as a negative control. Sections treated with DNAse to sample is divided by the CT value using the second se-
quence. Derivation of this fraction is independent ofintroduce DNA breaks in all nucleoli were used as posi-
tive control. RNA sample concentration, eliminating the requirement
to measure the RNA concentration accurately.
Urine reverse transcription-quantitative polymerase
chain reaction analysis Morphometric analysis
Images from at least 12 sequential glomerular cross-The TaqMan assay has been described previously
[37–39]. Briefly, the assay is based on the principle that sections at approximately the glomerular equator were
collected for each histologic section using the Metamorphsuccessful PCR yields a fluorescent signal due to Taq-
mediated exonuclease digestion of a fluorescently labeled Image System (Metamorph, Universal Imaging Corp.,
Downington, PA, USA) by a blinded observer (Y.H.K.).oligonucleotide homologous to a sequence between the
two primers. The extent of digestion, which depends The mean area of each glomerular profile was measured
by manually tracing the glomerular outline on a videodirectly on the amount of PCR that occurs, can be quanti-
fied directly and accurately by measuring the increment screen or encircling the area of interest and calculating
that area by computerized morphometry using the Imagein fluorescence that results from decreased energy trans-
fer. This sensitive measurement allows detection in the Measurement System (Jandel Sigma Scan 3.0, SPSS, Inc.,
Chicago, IL, USA). The number of podocytes in eachexponential phase of the PCR reaction that is required
for determination of abundance. For urine, this is accom- glomerular cross section as defined by GLEPP1 and the
WT1 immunoperoxidase staining was counted. The areaplished by performing the assay on an aliquot of the urine
sediment. The urine sediment was prepared from the in each glomerulus that was not stained by the GLEPP1
immunoperoxidase stain (GLEPP1 negative) or alterna-total urine collected over the course of a day. The urine
was spun, and the sediment was collected and resuspended tively was sclerosed as assessed by PAS staining, was also
traced manually, and was measured by computerizedin 0.5 mL RNAlater (Ambion, Austin, TX, USA). RNA
was isolated by spin chromatography through RNAEasy morphometry as outlined previously in this article. The
number of podocytes per glomerular volume was calcu-columns (Qiagen, GmbH, Hilden, Germany) in water
and frozen in five aliquots at 80C. lated by assuming that each glomerulus examined was
a 3 m-thick slice of a hemibisected sphere. Thus, theThe steady-state amount of mRNA was analyzed by
reverse transcription-quantitative polymerase chain re- counted number of podocytes present in the volume of
this slice was corrected for the complete spherical vol-action (RT-QPCR). The standard curve method (User
Bulletin #2; ABI PRISM 7700 Sequence Detection Sys- ume to calculate the number of podocytes per glomerular
volume. The GAPP was calculated by measuring the totaltem) was used for the measurement. We derived the RT-
QPCR ratio of the podocyte-specific markers, GLEPP1 glomerular area and dividing that number by the counted
number of podocytes in that glomerulus. The podocyteand nephrin [34, 40], to the constitutively expressed marker,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) covered GAPP (P-GAPP) was calculated by measuring
the glomerular area staining for GLEPP1 and dividingat different days after administration of puromycin. Since
absolute quantitation of RNA is difficult to achieve, a this area by the podocyte number counted in that glomer-
ular area.relative ratio approach was used in our calculation. Thus,
all of the measurements in this study were done using a Glomerular sclerosis was graded on GLEPP1 immu-
noperoxidase and PAS-stained sections. The scoring sys-GAPDH marker. This normalization procedure enabled
us to compare the expression of a given gene in two tem described by Saito et al was used as follows: 0,
normal glomerulus; 1, sclerosis involving less than 25%;urine sediments accurately without needing to know the
total amount of analyzable RNA in urine sediment. 2, sclerosis involving 25 to 50%; 3, sclerosis involving 50
to 75%; and 4, sclerosis involving 75 to 100% of glomeru-Reverse transcription was performed at 60 for 30 min-
utes. Following a subsequent ten-minute incubation at lar tuft area [41]. The sclerotic index was calculated as
follows: S.I.  [(n0  0)  (n1  1)  (n2  2)  (n3 95C to inactivate reverse transcriptase and activate
AmpliTaq Gold, PCR amplification was accomplished 3)  (n4  4)]/total glomeruli counted. More than 90
glomeruli from each rat were evaluated.in a two-step amplification (15 sec at 95C to denature
the DNA and 1 min at 60C to permit annealing and
Statistical analysiselongation). To assay the initial concentration of the
reactants (the abundance), the number of cycles at which The mean number was calculated for each animal.
This value was used for statistical analysis using analysisthe reaction crosses a threshold value was measured.
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of variance. All values were expressed as mean  SEM.
A P value of less than 0.05 was considered to be statisti-
cally significant.
RESULTS
A single intraperitoneal injection of PAN (20 mg/100 g
body weight) was used to assess the effect on glomerular
podocyte number. Acute podocyte injury and protein-
uria was induced as is well described from numerous
prior studies (Fig. 1). The structural changes to the podo-
cyte included pseudocyst formation and effacement of
foot processes, as assessed by transmission electron mi-
croscopy (data not shown).
For initial studies, GLEPP1 was used as a marker of
podocytes. A decrease in podocyte number per area was
measured as shown in Figure 1. To confirm the observa-
tion, a second set of independent measurements was
made using WT1 as a marker of podocytes. Very similar
results were obtained with both the GLEPP1 and WT1
systems (Fig. 1). Over an 11-day period after PAN injec-
tion, the glomerular podocyte count dropped signifi-
cantly below control levels and remained significantly
below control for 126 days.
To address the question of whether this reduction in
podocyte count was real or an artifact due to an increase
in glomerular size after PAN injection, the number of
podocytes per glomerular volume was calculated at the
126 day time point, by which time the glomerular vol-
umes were not different between the experimental and
control groups (6.0  0.8 vs. 6.2  0.4  105m3). At
this time, the mean number of podocytes per glomerular
volume was 281  18 for PAN-treated and 387  18 for
time control, respectively (P  0.01). We concluded that
the number of podocytes per glomerulus appeared to
have decreased by approximately 27%, and that this re-
duction occurred between 5 and 11 days following PAN
injection.
If podocytes were being lost, then it should be possible
to visualize this process by structural analysis. Therefore,
histologic sections stained by immunoperoxidase were
examined for the podocyte marker GLEPP1 (Fig. 2).
GLEPP1-positive cells that appeared to be detached from
the GBM were present in Bowman’s space (Fig. 2A).
Transmission electron microscopy (TEM) analysis also
showed detached rounded up cells in Bowman’s space
(Fig. 2C). Toluidine blue-stained one-micron sections
Fig. 1. Time-course of variables measured in groups of rats following
intraperitoneal injection of puromycin aminonucleoside (PAN). (A) podocytes per glomerular area occurring by day 5. (C) The Thy-1–
Twenty-four–hour urine protein excretion beginning by day 3 after positive cell count per glomerular area that is significantly increased by
PAN injection. (B) Mean podocyte counts per glomerular area with day 21 after PAN injection (P  0.01). (D) The sclerotic index (mea-
podocytes being measured as either GLEPP1-positive cell nuclear num- sured as indicated in the methods section) indicating that the amount
ber () or as WT1–positive cells (). The controls are measured as of glomerulosclerosis seen in this single PAN injection model is small
GLEPP1-positive cell nuclear number (). The significant decrease in and is present by day 45 after PAN injection.
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Fig. 2. Histologic sections from glomeruli of
day 5 to day 7 rats after PAN injection. (A)
Immunoperoxidase staining for GLEPP1 coun-
terstained with PAS showing detached podo-
cyte stained with GLEPP1 (arrowhead) in Bow-
man’s space. (B) Toluidine blue-stained one
micron section showing cells in Bowman’s
space some of which have dense pyknotic nu-
clei (arrowhead). (C) TEM showing detached
cells in Bowman’s space (arrowhead) adjacent
to injured podocytes containing pseudocysts
(*). (D) TUNEL-positive cell in the glomeru-
lus (arrowhead).
cells were present in Bowman’s space that had features in Figure 3. No signal was detected in urine of normal
rats. However, four to five days after injection of PAN,of apoptotic cells (Fig. 2B). Therefore, TUNEL staining
for apoptotic cells also was performed at various times a positive signal GLEPP1 was detected in all of the three
rats examined. No further signal was detected in theafter PAN injection. TUNEL-positive cells were present
in glomeruli at days five to seven after PAN injection subsequent days after a single PAN injection. Thus, al-
though detached cells might be in the process of apopto-(Fig. 2D). TUNEL-positive cells were not seen either in
control glomeruli or glomeruli at later times after the sis, at least some of the detached cells maintained intact
mRNA long enough to be detected in the urine in spitesingle PAN injection. Taken together, these data support
the concept that podocytes are lost from glomeruli in of the apoptotic process. The finding that a positive signal
was seen on only one day (presumably the peak of cellthe 5- to 11-day interval following PAN injection in the
rat. This loss may be a combination of cell detachment loss into the urine) suggested that the assay might be
insensitive or the signal might be weak possibly due toand cell death with apoptosis as one possible mechanism
involved. apoptosis of detached podocytes.
By day 20 after PAN injection, the number of Thy-1–To examine the hypothesis that podocytes were being
lost from glomeruli in the days after PAN injection, the positive cells in glomeruli had increased (Fig. 1C). Since
leukocytes as well as mesangial cells are Thy-1 positive,urine was analyzed for evidence of podocyte loss using
an RT-PCR approach. Primers for the podocyte-specific we cannot discriminate between these cell types from
this analysis. However, the increase in Thy-1–positive cellsproteins GLEPP1 were used, and the results are shown
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Fig. 3. Ratios of GLEPP1 mRNA:GAPDH mRNA as measured using
the TaqMan assay. All three rats examined had GLEPP1 mRNA detect-
able in urine at days 4 to 5. Urines were negative at other time points.
and mesangial matrix had occurred by day 20, which was
after the decrease in podocyte count, which occurred by
day 11 in this model. Adhesions to Bowman’s capsule
also were present by day 20 after PAN injection. Glomer-
ulosclerosis was not a prominent feature of the single
PAN injection model, but was present in increasing
amount by day 45 in the model (Fig. 1D). Thus, the tempo-
ral sequence of events was first proteinuria (seen by day
3), followed by a reduction in podocyte number (by day
11), and then by an increase in Thy-1–positive cells and
early adhesions to Bowman’s capsule (by day 20), and
finally the appearance of glomerulosclerosis (by day 45).
If podocytes are being depleted in this model, then it
should be possible to reduce the glomerular podocyte
count further by sequential injections of PAN. To assess
the effect of additional podocyte depletion, a second set
of experiments was performed where rats received none,
one, two, or three injections of PAN at the same dose per
body weight at 30-day intervals, and animals were killed
for analysis at 90 days. The results of this study are shown
in Figure 4. Each injection of PAN caused an additional
amount of podocyte depletion, additional glomeruloscle-
rosis, and an additional degree of proteinuria. Represen-
tative histologic sections stained for GLEPP1, WT1, and
by PAS for glomerulosclerotic area are shown in Figure
5. The region of the glomerulus that was glomerulo-
sclerotic (PAS positive) corresponded to the area of the
Fig. 4. Effect of sequential injections of PAN at 30-day intervals. Eachglomerulus that did not contain podocytes as defined by
injection resulted in an increase in protein excretion (A), a reductionspecific markers (GLEPP1 and WT1). The correlation in the number of podocytes per glomerular volume as measured by
between the GLEPP1-negative area and the PAS-posi- counting WT-1–positive cells (B), and an increase in glomerulosclerosis
as measured by PAS-positive glomerular area (C). Symbols in A are:tive area (measured independently in different histologic
() one; () two; () three.sections) is shown in Figure 6. We conclude that the area
of the glomerulus without podocytes (GLEPP1 negative)
corresponds closely to the glomerulosclerotic area.
Injury to podocytes results in an increase in glomerular
volume, which is manifest by an increase in the glomerular
area when seen in a two-dimensional image. The glomeru-
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Fig. 5. Sequential histologic sections of control rats (A0, B0, C0), one PAN injection (A1, B1, C1), two PAN injections (A2, B2, C2), and three
PAN injections (A3, B3, C3). Sections labeled A show immunoperoxidase staining for GLEPP1 and counterstained with PAS. Sections labeled
B show immunoperoxidase staining for WT1. Sections labeled C show PAS staining to identify area of glomerulosclerosis. The arrows indicate
areas of glomerulosclerosis in the PAN-treated animals. Arrowheads in A and B sections shows podocytes as identified by GLEPP1 staining (A)
and WT1 staining (B).
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Fig. 6. Correlation between GLEPP1-negative area and PAS-positive
area for groups of rats receiving one, two, or three PAN injections was
high (r2 	 0.9).
Fig. 8. Glomerular area per podocyte (GAPP) shown in two different
ways. (A) The podocyte-containing (GLEPP1 positive) area per podo-
cyte (P-GAPP). In this case, there is an increase in area per podocyte
by 1.6-fold after the first PAN injection, but no further increase after
subsequent injections. (B) The total GAPP. In this case, the area per
podocyte continues to increase up to the third injection of PAN because
the area of sclerosis is increasing even as the number of podocytes is
decreasing as shown in Figure 7. Thus, the GAPP measure the glomeru-
lar area sclerosed plus the glomerular area containing podocytes. Sym-
bols are: () GLEPP1; () WT1.
Fig. 7. Mean total glomerular area (), the GLEPP1-positive glomeru-
lar area (containing podocytes; ) and the PAS-positive glomerular To determine whether podocytes were capable of serv-
area (glomerulosclerotic area; ) are shown from control, one, two
ing a larger area of the glomerulus after PAN injury, theand three PAN injection rat groups. After one PAN injection, there
was a 30% increase in glomerular area. This was accompanied by a glomerular area was expressed in terms of the number
smaller increase in GLEPP1-positive area and a small amount of glo- of podocytes present in relationship to glomerular area.
merulosclerosis, indicating that there was some potential for podocytes
This can be expressed as total glomerular area (normalto cover an increased area after a single PAN injection. After two PAN
injections, there was no further increase in total glomerular area. The plus sclerotic area) per podocyte (GAPP) or as the podo-
GLEPP1-positive area had decreased in association with a reduction cyte-containing glomerular area (GLEPP1-positive area)
in the number of podocytes and glomerulosclerosis had increased. After
per podocyte (P-GAPP). As shown in Figure 8A, therethree PAN injections, there was a further decrease in the GLEPP1-
positive area and an increase in glomerulosclerosis. was a 60% increase in P-GAPP after the first injection
of PAN. However, with subsequent injections of PAN,
there was no further increase in P-GAPP. Thus, we con-
cluded that a podocyte can significantly increase the areaslar area increased after the first PAN injection by approx-
it serves by approximately 60%. The reduction in podo-imately 1.3-fold (Fig. 7). The total glomerular area re-
cyte count after the second and third injection of PANmained at this increased level with subsequent injections
was not reflected by a further increase in area served byof PAN (Fig. 7). However, the proportion of the glomer-
each podocyte (P-GAPP), but rather by an increase inular area that was GLEPP1 positive (occupied by podo-
glomerular area without podocytes. Thus, the maximumcytes and with normal glomerular structure) progres-
P-GAPP was approximately 1.6-fold the normal value.sively decreased with each injection of PAN (Fig. 7) to
In contrast, the GAPP continued to increase with eachbe replaced by a GLEPP1 and WT1-negative area with
the typical features of glomerulosclerosis (Fig. 5). PAN injection as scarring formed an increasingly large
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Fig. 9. Data expressed as percent of normal
glomerular podocytes per glomerular volume
and plotted against glomerulosclerosis as mea-
sured by PAS-positive area (A) or GLEPP1-
negative area (B). In each case, there is a high
correlation between these variables for the
groups of rats treated by one, two or three
injections of PAN (r2 	 0.9). The Y intercept
indicates the proportion of the normal podo-
cyte complement that would need to be lost
per glomerulus before glomerulosclerosis would
occur. This value is approximately 10 to 20%.
proportion of the glomerular area (Fig. 8B). Thus, glo- to undergo a phenotypic switch that may be analogous
merulosclerosis developed beyond a particular threshold to dedifferentiation toward a phenotype that possibly has
value for GAPP (total GAPP) of approximately 1.6 times the capacity to undergo cell division [4, 30]. In our study
the normal value. in rats, there was an apparent reduction in the number
To evaluate the relationship between podocyte deple- of podocytes per glomerulus following PAN injection as
tion and glomerulosclerosis in a continuous way, the measured by WT1 and GLEPP1 staining. It is therefore
data for the groups of animals were plotted with percent possible that these markers could merely have been ab-
normal podocyte number per glomerular volume against sent from damaged podocytes and therefore not visible
the proportion of the glomerulus that was glomerulo- under the conditions used, which would render the con-
sclerotic as measured either by PAS-positive area or by clusions and interpretation of these studies invalid. We
GLEPP1-negative area (Fig. 9). The r2 values show that think this is unlikely for the following reasons. First, the
there was a very close relationship between the propor- experiments described here were originally performed
tion of normal podocyte number remaining after each with the hypothesis based on our previous report in hu-
PAN injection and amount of glomerulosclerosis, as as- man renal biopsies that identified phenotypically changed
sessed by either method. Furthermore, the intercept on cells that had lost their markers (GLEPP1 and WT1)
the Y axis at approximately 80 to 90% for the two meth- following PAN injection [42, 44]. Thus, we looked care-
ods of analysis indicates that there is a theoretical thresh- fully for such cells to attempt to support this hypothesis,
old of podocyte number below which glomerulosclerosis but were unable to find them. Second, if cells do lose
would be expected to occur. This number was at approxi- their markers in association with injury, we would expect
mately 80 to 90% of the normal podocyte number for them to regain their markers after time when the injury
the rats studied. Thus, after the first PAN injection, the had diminished as assessed by decreased proteinuria to
glomerular area increased by 1.3-fold (Fig. 7), and the the normal range. As shown in Figure 1, even after 126
podocyte count decreased by approximately 20% with
days following PAN injury, there was no increase in
small amount of glomerulosclerosis occurring. This com-
number of podocytes back toward the control range,
bination of increased glomerular area and decreased po-
as identified by the WT1 and GLEPP1 markers. Third,docyte number resulted in each podocyte having about
podocytes (positive for GLEPP1) were identified as be-a 1.5- to 1.6-fold increase in its normal territory (1.3
coming detached from glomeruli and having an apoptoticdivided by 0.8) as is shown in Figure 8. Above this range,
phenotype as assessed by TUNEL staining, and podo-glomerulosclerosis became prominent.
cyte-specific mRNA appearing in the urine was indepen-
dent evidence that podocytes were being lost from the
DISCUSSION glomeruli. Thus, we conclude that the data cannot be
explained in terms of a phenotypic switch to a podocyteThis study used immunohistochemical markers
without the GLEPP1 and WT1 markers as we had origi-(GLEPP1 and WT1) to define a podocyte. Under some
nally hypothesized. Rather, there was a real loss of podo-circumstances in human renal biopsies, podocytes may
cytes from glomeruli following PAN injection.lose these markers, as has been described in collapsing
As has been suggested by Kriz, Gretz, and Lemley, anand human immunodeficiency virus (HIV)-associated
important biological question is whether podocytes areglomerulosclerosis [30, 42] and possibly also in crescentic
nephritis [43]. In both of these cases, podocytes appear able to cover adequately the area of GBM “assigned” to
Kim et al: Podocyte depletion966
them and thereby maintain the filtration characteristics The experimental results described in this report are
compatible with the hypothesis that podocyte damageof the glomerular filter [1–5]. Failure to do this results in
“nude areas” causing in a predisposition to form adhesions leading to podocyte depletion itself results in glomerulo-
sclerosis in the rat PAN model. The observation that glo-to Bowman’s capsule and probably also to mesangial ex-
pansion, which are the hallmarks of glomerulosclerosis. merulosclerosis occurred in that area of the glomerulus
where podocytes were absent (as defined by GLEPP1Two related events occur following injury to the podo-
cyte by PAN. One event is a decrease in podocyte num- and WT1 markers) would be compatible with the concept
that glomerulosclerosis might be the direct result of theber, as shown previously in this article, and the other is
an increase in glomerular size. With this concept in mind, absence of podocytes at a particular site in the glomerulus.
The finding that the glomerular area that can be servedthe most important variable to measure is one that takes
both these factors into account. This is conveniently con- per podocyte (P-GAPP) remained constant over the dif-
ferent levels of injury suggests that each podocyte hassidered as the number of podocytes per unit area. While
it is very difficult to measure glomerular basement mem- limited capacity to serve a larger glomerular area. The
data provided suggest that the threshold above whichbrane area directly because of the three-dimensional con-
voluted structure of the GBM, it is not difficult to mea- glomerulosclerosis develops is about 1.5- to 1.6-fold the
normal value for GAPP. However, this conclusion mustsure a derivative of it, namely, the number of podocytes
per unit area on a glomerular tuft cross-section. In this be tempered by the consideration that all podocytes were
injured by PAN in this model, so the recovered podo-report, we have designated this variable as the GAPP. A
further useful and related variable is the glomerular area cytes may have sustained damage that could affect the
capacity to cover expanded territory.actually served by podocytes or P-GAPP. The P-GAPP
was measured using the marker GLEPP1 to define the Podocyte injury/loss and glomerular expansion was
completed by day 11 of the PAN model. By day 20, theglomerular area served by podocytes. The GAPP and
P-GAPP therefore provide different information. These number of Thy-1–positive cells and mesangial expansion
had increased, and adhesions between Bowman’s cap-two variables are useful as we try to understand podocyte
pathology in the context of the glomerulus. sule and the outer glomerular capillary loops had oc-
curred. Thy-1–positive cells are largely mesangial cells,A third question is the measurement of the absolute
number of podocytes per glomerulus. Since glomeruli although it is possible that the count could include some
macrophages or T cells that could participate in drivingare in general spherical, it is assumed that a cell count
made at the equator of a glomerulus in a section of the sclerotic process in this model [36]. The process of
formation of adhesions between capillary loops and Bow-known thickness and measured diameter can be used to
calculate the number of podocytes per whole glomerular man’s capsule as a consequence of denudation of the
glomerular filtration surface has been described and mod-volume. This method was used for some of the analyses
(Fig. 4) where the data were expressed as podocytes per eled by Kriz, Gretz, and Lemley [3, 4]. The time course
of mesangial expansion could reflect a similar processglomerular volume. Because these counts were made by
a blinded investigator, were done for twelve consecutive occurring in the mesangial compartment due to loss of
podocytes from the capillary loop in areas adjacent toglomeruli, and were used to compare animals between
treatment groups, this is a reasonable approach. How- the mesangium. Thus, the same process (podocyte loss/
injury) resulting in an increased GAPP might lead toever, as with any method that relies on projections based
on a sample of the whole, errors will tend to be multiplied. both adhesions to Bowman’s capsule and mesangial
expansion depending on where in the glomerulus theTo partially address this question, we chose to compare
the podocyte counts in glomeruli of rats after 126 days podocyte loss occurred. This concept would help explain
the focal nature of focal segmental glomerulosclerosiswhen the size of glomeruli was not different between
the treated group and age-matched animals from the (FSGS), a poorly understood but obviously important
phenomenon seen in many glomerular diseases.same batch of rats. The podocyte counts were signifi-
cantly reduced (by 27%) in the PAN-treated group. Thus, The concept of a variable degree of podocyte reserve
and depletion of podocytes to a critical level beyondat least in this case, glomerular size did not confound
the estimate of the total podocyte calculation. Other which glomerulosclerosis occurs is a potentially impor-
tant one. Such a concept would complement the resultsexperimental approaches that use ultrastructure are lim-
ited by the number of podocytes that can be measured of Pagtalunan et al, who measured podocyte number in
diabetic Pima Indians [31, 32]. There appeared to be apractically, and therefore by the sample size and selec-
tion bias, as well as by three-dimensional limitations and threshold for GAPP in the Pima Indian population. Be-
low this GAPP threshold, there was no proteinuria ordifficulties in deciding where one podocyte begins and
another ends [31]. Both methods have resulted in similar glomerulosclerosis. Above this range, proteinuria and
glomerulosclerosis developed.conclusions, namely that podocyte counts per glomerulus
are reduced under certain pathologic conditions. Further studies are required to determine how differ-
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ent genetic factors affect the glomerular complement of It would be expected that cells were being lost into the
urine over several days after PAN injection. This sug-podocytes at birth and over a lifetime, and indeed whether
gests that the method, as it was set up in this set ofdecrements in podocyte number do in fact accompany
studies, was rather insensitive in that it only detected thethe glomerulosclerostic process in human glomerular dis-
peak day of podocyte excretion. With further refinement,eases. If particular human individuals or groups were to
the detection and characterization of mRNAs in urinehave a lower podocyte reserve on the basis of genetic or
may prove to be a useful adjunct to traditional methodsenvironmental influences, then this might help to explain
of urine analysis and in particular might prove usefulsusceptibility to progression to ESRD from hyperten-
for monitoring podocyte excretion in the clinical settingsion, diabetes, FSGS, and other glomerular diseases.
using automated techniques.Factors that might facilitate detachment of podocytes
The concept of progressive podocyte loss, finite podo-from the GBM would likely play a permissive role in
cyte reserve, and development of glomerulosclerosis as apodocyte depletion over time. Drenckhahn and Franke,
consequence of podocyte loss beyond a critical thresholdand Whiteside et al have already shown that podocyte
would also provide support for a rational explanationdetachment occurs in the PAN model in the rat and pro-
of why angiotensin-converting enzyme inhibitors are sovided an interesting mathematical analysis of how partial
effective at preventing progression in many forms of glo-detachment would predispose to further detachment
merular disease including diabetes [49]. The effect of[5, 12]. We know from other cell systems that epithelial
angiotensin-converting enzyme (ACE) inhibitors to de-cell detachment from the underlying matrix triggers apo-
crease intraglomerular pressure would likely be impor-ptosis [45]. Therefore, the finding of TUNEL-positive
tant in reducing the rate of podocyte detachment. Indeed,cells and detached cells with nuclear features suggestive
in the PAN model, ACE inhibitors have been shown to
of apoptosis is not surprising. Hara et al have also docu- reduce proteinuria and the degree of glomerular injury
mented podocyte loss into the urine in human glomerular [50]. The ACE inhibitor effect could well occur via sev-
diseases [33]. Factors such as intraglomerular hyper- eral mechanisms, but reduction in podocyte detachment
tension, immune complexes, and insertion of C5-9 into is an attractive and plausible one. This mechanism would
podocytes might well promote podocyte detachment/ complement the hyperfiltration concept promoted by
apoptosis. Factors that affect the GBM such as diabetes, Brenner, Lawler, and Mackenzie [51]. A loss of podocytes
amyloidosis, and immune complexes also could affect over time could also be an important factor helping to
the ability of podocytes to remain attached to the GBM explain the remarkable increase in incidence of ESRD
through integrins and other mechanisms. In this setting, seen as the human population ages, as has been noted
underlying genetic factors that reduce adherence of po- for the aging Milan normotensive rat [29].
docytes to the filter surface might predispose an individ- Taken together, the results from this report provide
ual to develop glomerulosclerosis. One such factor has support for a potentially important mechanism underly-
recently been described as the cause of late onset familial ing progression of glomerular injury, and draws attention
FSGS in humans [46]. In this case, the mutated protein is to the need to understand podocyte biology and the role

-actinin 4, a protein responsible for linking the integrin of podocytes in glomerular diseases better.
molecule to the cytoskeleton of the podocyte. Integrins
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